247 related articles for article (PubMed ID: 32504402)
21. Epigenetic programming of pediatric high-grade glioma: Pushing beyond proof of concept to clinical benefit.
Groves A; Cooney TM
Front Cell Dev Biol; 2022; 10():1089898. PubMed ID: 36589742
[TBL] [Abstract][Full Text] [Related]
22. Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition.
Mondal G; Lee JC; Ravindranathan A; Villanueva-Meyer JE; Tran QT; Allen SJ; Barreto J; Gupta R; Doo P; Van Ziffle J; Onodera C; Devine P; Grenert JP; Samuel D; Li R; Metrock LK; Jin LW; Antony R; Alashari M; Cheshier S; Whipple NS; Bruggers C; Raffel C; Gupta N; Kline CN; Reddy A; Banerjee A; Hall MD; Mehta MP; Khatib Z; Maher OM; Brathwaite C; Pekmezci M; Phillips JJ; Bollen AW; Tihan T; Lucas JT; Broniscer A; Berger MS; Perry A; Orr BA; Solomon DA
Acta Neuropathol; 2020 Jun; 139(6):1071-1088. PubMed ID: 32303840
[TBL] [Abstract][Full Text] [Related]
23. Molecular characteristics of pediatric high-grade gliomas.
Chamdine O; Gajjar A
CNS Oncol; 2014 Nov; 3(6):433-43. PubMed ID: 25438814
[TBL] [Abstract][Full Text] [Related]
24. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
25. Targeting reduced mitochondrial DNA quantity as a therapeutic approach in pediatric high-grade gliomas.
Shen H; Yu M; Tsoli M; Chang C; Joshi S; Liu J; Ryall S; Chornenkyy Y; Siddaway R; Hawkins C; Ziegler DS
Neuro Oncol; 2020 Jan; 22(1):139-151. PubMed ID: 31398252
[TBL] [Abstract][Full Text] [Related]
26. ATM inhibition enhances the efficacy of radiation across distinct molecular subgroups of pediatric high-grade glioma.
Xie J; Kuriakose T; Bianski B; Twarog N; Savage E; Xu K; Zhu X; He C; Hansen B; Wang H; High A; Li Y; Rehg JE; Tillman HS; Freeman BB; Rankovic Z; Onar-Thomas A; Fan Y; Wu G; Peng J; Miller S; Baker SJ; Shelat AA; Tinkle CL
Neuro Oncol; 2023 Oct; 25(10):1828-1841. PubMed ID: 36971093
[TBL] [Abstract][Full Text] [Related]
27. Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Stegmaier K; Bourdeaut F; Reaman G; Heenen D; Meyers ML; Armstrong SA; Brown P; De Carvalho D; Jabado N; Marshall L; Rivera M; Smith M; Adamson PC; Barone A; Baumann C; Blackman S; Buenger V; Donoghue M; Duncan AD; Fox E; Gadbaw B; Hattersley M; Ho P; Jacobs I; Kelly MJ; Kieran M; Lesa G; Ligas F; Ludwinski D; McDonough J; Nikolova Z; Norga K; Senderowicz A; Taube T; Weiner S; Karres D; Vassal G
Eur J Cancer; 2020 Nov; 139():135-148. PubMed ID: 32992153
[TBL] [Abstract][Full Text] [Related]
28. Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma.
Rosenberg T; Yeo KK; Mauguen A; Alexandrescu S; Prabhu SP; Tsai JW; Malinowski S; Joshirao M; Parikh K; Farouk Sait S; Rosenblum MK; Benhamida JK; Michaiel G; Tran HN; Dahiya S; Kachurak K; Friedman GK; Krystal JI; Huang MA; Margol AS; Wright KD; Aguilera D; MacDonald TJ; Chi SN; Karajannis MA
Neuro Oncol; 2022 Nov; 24(11):1964-1975. PubMed ID: 35397478
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.
Johnson A; Severson E; Gay L; Vergilio JA; Elvin J; Suh J; Daniel S; Covert M; Frampton GM; Hsu S; Lesser GJ; Stogner-Underwood K; Mott RT; Rush SZ; Stanke JJ; Dahiya S; Sun J; Reddy P; Chalmers ZR; Erlich R; Chudnovsky Y; Fabrizio D; Schrock AB; Ali S; Miller V; Stephens PJ; Ross J; Crawford JR; Ramkissoon SH
Oncologist; 2017 Dec; 22(12):1478-1490. PubMed ID: 28912153
[TBL] [Abstract][Full Text] [Related]
30. Receptor tyrosine kinase (RTK) targeting in pediatric high-grade glioma and diffuse midline glioma: Pre-clinical models and precision medicine.
Schwark K; Messinger D; Cummings JR; Bradin J; Kawakibi A; Babila CM; Lyons S; Ji S; Cartaxo RT; Kong S; Cantor E; Koschmann C; Yadav VN
Front Oncol; 2022; 12():922928. PubMed ID: 35978801
[TBL] [Abstract][Full Text] [Related]
31. Invited Review: Emerging functions of histone H3 mutations in paediatric diffuse high-grade gliomas.
Kasper LH; Baker SJ
Neuropathol Appl Neurobiol; 2020 Feb; 46(1):73-85. PubMed ID: 31859390
[TBL] [Abstract][Full Text] [Related]
32. Resistance mechanisms in BRAF
Lehmann R; Rayner BS; Ziegler DS
Front Oncol; 2022; 12():1031378. PubMed ID: 36582791
[TBL] [Abstract][Full Text] [Related]
33. Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism.
Morel D; Almouzni G; Soria JC; Postel-Vinay S
Ann Oncol; 2017 Feb; 28(2):254-269. PubMed ID: 28426098
[TBL] [Abstract][Full Text] [Related]
34. Emerging Advances in Combinatorial Treatments of Epigenetically Altered Pediatric High-Grade H3K27M Gliomas.
Leszczynska KB; Jayaprakash C; Kaminska B; Mieczkowski J
Front Genet; 2021; 12():742561. PubMed ID: 34646308
[TBL] [Abstract][Full Text] [Related]
35. No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3.
Wiese M; Schill F; Sturm D; Pfister S; Hulleman E; Johnsen SA; Kramm CM
Klin Padiatr; 2016 Apr; 228(3):113-7. PubMed ID: 27135271
[TBL] [Abstract][Full Text] [Related]
36. The growing role of epigenetics in childhood cancers.
Panditharatna E; Filbin MG
Curr Opin Pediatr; 2020 Feb; 32(1):67-75. PubMed ID: 31895160
[TBL] [Abstract][Full Text] [Related]
37. Downregulation of miR-137 and miR-6500-3p promotes cell proliferation in pediatric high-grade gliomas.
Liang ML; Hsieh TH; Ng KH; Tsai YN; Tsai CF; Chao ME; Liu DJ; Chu SS; Chen W; Liu YR; Liu RS; Lin SC; Ho DM; Wong TT; Yang MH; Wang HW
Oncotarget; 2016 Apr; 7(15):19723-37. PubMed ID: 26933822
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells.
Was H; Krol SK; Rotili D; Mai A; Wojtas B; Kaminska B; Maleszewska M
Clin Epigenetics; 2019 Jan; 11(1):11. PubMed ID: 30654849
[TBL] [Abstract][Full Text] [Related]
39. High-throughput microRNA profiling of pediatric high-grade gliomas.
Miele E; Buttarelli FR; Arcella A; Begalli F; Garg N; Silvano M; Po A; Baldi C; Carissimo G; Antonelli M; Spinelli GP; Capalbo C; Donofrio V; Morra I; Nozza P; Gulino A; Giangaspero F; Ferretti E
Neuro Oncol; 2014 Jan; 16(2):228-40. PubMed ID: 24305714
[TBL] [Abstract][Full Text] [Related]
40. Molecular pathogenesis and therapeutic implications in pediatric high-grade gliomas.
Juratli TA; Qin N; Cahill DP; Filbin MG
Pharmacol Ther; 2018 Feb; 182():70-79. PubMed ID: 28830841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
